Business Wire

MICROSURE

7.6.2019 12:39:10 CEST | Business Wire | Press release

Share
Microsure’s MUSA Microsurgery Robot Receives CE-mark

MUSA is the world’s first surgical robot for open microsurgery. This robotic assistant is clinically and commercially available after the medical device CE-mark was issued by notified body DEKRA recently. Microsure’s MUSA is developed by a team of microsurgeons and engineers, creating a high-precision robotic assistant that is compatible with current operating techniques, workflow, instruments and other OR-equipment. It enhances surgical performance by stabilizing and scaling down the surgeon’s movements during complex microsurgical procedures on sub-millimeter scale.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190607005175/en/

Microsure’s MUSA e.g. enables lymphatic surgery on lymph vessels smaller than 0.3 mm in diameter. Plastic surgeons at Maastricht University Medical Center+ were the first to use MUSA to surgically treat lymphedema in a patient. This world's premier super-microsurgical intervention with 'robot hands' took place in 2017. Maastricht University Medical Center+ is now conducting several follow up clinical research projects with MUSA, in different fields of microsurgery. Other European hospitals are expected to start clinical studies this year.

Microsurgery procedures with MUSA

Surgical procedures that maximally benefit from Microsure’s MUSA are complex surgeries on small tissue structures –for instance LVA (Lymphovenous Anastomosis) surgery, pediatric vascalar surgery, free flap surgery, finger and hand replantation – when human precision is the limiting factor because of physiological tremor, poor accessibility or fatigue. Various studies and pilots have proven safe and effective clinical use of the device.

ISO 13485 certification

Microsure also received the ISO 13485 certificate, another major milestone. The ISO certification assures that Microsure is adhering to the highest standards in quality management and regulatory compliance procedures to develop, manufacture, and test its products and services. ISO 13485:2016 is the latest update to ISO requirements for a comprehensive quality management system for the design and manufacture of medical devices.

Microsure

Microsure is a medical device company in Eindhoven (The Netherlands) founded by Eindhoven University of Technology and Maastricht University Medical Center in 2016, funded by Innovation Industries Fund. Microsure’s focus is to improve patients’ quality of life through developing robot systems for microsurgery. Its current product is MUSA, the world’s first surgical robot for open microsurgery. MUSA has been designed by microsurgeons and engineers, specifically for microsurgical applications. MUSA provides superhuman precision for microsurgeons, enabling new interventions that are currently impossible to perform by hand. www.microsure.nl

Contact:

Microsure Lars Schiemanck (CEO) l.schiemanck@microsure.nl +31 686 692 887

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 14:00:00 CET | Press release

Alliance Brings Seamless Integration of Asset Data into ArcGIS for PIX4Dcatch Users Pix4D joins with Esri to launch new terrestrial scanning workflow for infrastructure-focused organizations. Esri and Pix4D workflow lets field teams capture accurate 3D models and augmented reality using PIX4Dcatch app data integrated directly into ArcGIS Online in real time. New integration enables users to document subsurface assets with seamless precision. Workflow brings high-fidelity, georeferenced documentation and instant verification to the project lifecycle for improved accuracy. Explore the PIX4Dcatch app and publish 3D data to ArcGIS Online. Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Es

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 14:00:00 CET | Press release

Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 12:30:00 CET | Press release

Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to achieve in TRDCOMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profileIn COMP006, two doses of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by MADRS2 with a mean difference of -3.8 comparing 25 mg to 1 mg (p<0.001)3Clinically meaningful reduction in MADRS (≥ 25%) observed in significant number of participants in 25mg arm of both trials with 25% in COMP005 and 39% in COMP006Statistically significant rapid onset from the day following administration maintained at all measured timepoints through Week 6 in both clinical trials in the 25 mg armIn COMP005, participa

BeOne Medicines to Present at Upcoming Investor Conferences17.2.2026 12:00:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Company will participate in fireside chats at four upcoming investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET; Leerink Global Healthcare Conference on Monday, March 9, 2026 at 11:20 am ET; Citizens Life Sciences Conference on Tuesday, March 10, 2026 at 9:35 am ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 pm ET Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel the

CTC Global Launches GridVista System and Strategic Partnership with Google Cloud and Tapestry to Transform Grid Intelligence17.2.2026 12:00:00 CET | Press release

New technology redefines transmission line intelligence, delivering continuous, high-resolution data across the entire length of the transmission line CTC Global, the world’s leading developer and manufacturer of high-capacity advanced conductors, today announced the launch of the GridVista System. The GridVista System provides utilities with real-time, high-resolution data to optimize grid capacity, prevent outages, reduce wildfire risk, and lower operational costs. With the launch of the GridVista System, CTC is also announcing a deepening of its strategic partnership with Google Cloud and Tapestry—Alphabet’s moonshot for the electric grid. GridVista System’s unprecedented line awareness, paired with Google Cloud and Tapestry’s AI-powered tools, will transform line data into actionable intelligence for the grid. The GridVista System redefines transmission line intelligence by utilizing optical fibers embedded directly within CTC Global’s ACCC Conductor. Unlike legacy technology that

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye